Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 14/20 | 0.59 |
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL697520 | 0.98 | CYP19A1 (0.57) | CYP19A1MAOBPKMTSHRSIGMAR1 | |
| SCHEMBL2381366 | 0.81 | CYP19A1 (0.59) | CYP19A1MAOBPKMTSHRSIGMAR1 | |
| SCHEMBL20165977 | 0.81 | CYP19A1 (0.59) | CYP19A1MAOBPKMTSHRSIGMAR1 | |
| SCHEMBL18415628 | 0.78 | CYP19A1 (0.61) | CYP19A1MAOBPKMTSHRSIGMAR1 | |
| SCHEMBL9835237 | 0.78 | CYP19A1 (0.56) | CYP19A1MAOBPKMTSHRSIGMAR1 | |
| SCHEMBL768947 | 0.77 | CYP19A1 (0.59) | CYP19A1MAOBPKMTSHRSIGMAR1 | |
| SCHEMBL68086 | 0.77 | CYP19A1 (0.59) | CYP19A1MAOBPKMTSHRSIGMAR1 | |
| SCHEMBL15147097 | 0.77 | CYP19A1 (0.59) | CYP19A1MAOBPKMTSHRSIGMAR1 | |
| SCHEMBL7241604 | 0.77 | CYP19A1 (0.59) | CYP19A1MAOBPKMTSHRSIGMAR1 | |
| SCHEMBL8748082 | 0.77 | CYP19A1 (0.47) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110770211-B | Alpha, beta unsaturated amide compound | 协和麒麟株式会社 | 2023-09-19 | — | — | CN | disclosed |
| CN-108430972-B | Alpha, beta-unsaturated amide compound | 协和麒麟株式会社 | 2022-12-27 | — | — | CN | disclosed |
| US-11447471-B2 | α,β-unsaturated amide compound | KYOWA KIRIN CO., LTD. (JP) | 2022-09-20 | — | — | US | disclosed |
| US-11332455-B2 | α,β-unsaturated amide compound | KYOWA KIRIN CO., LTD. (JP) | 2022-05-17 | — | — | US | disclosed |
| US-20210380551-A1 | ALPHA,BETA-UNSATURATED AMIDE COMPOUND | KYOWA KIRIN CO., LTD. (JP) | 2021-12-09 | — | — | US | disclosed |
| US-20210155612-A1 | Alpha,Beta-UNSATURATED AMIDE COMPOUND | KYOWA KIRIN CO., LTD. (JP) | 2021-05-27 | — | — | US | disclosed |
| US-10787428-B2 | α,β-unsaturated amide compound | KYOWA KIRIN CO., LTD. (JP) | 2020-09-29 | — | — | US | disclosed |
| EP-3712129-A1 | ALPHA, BETA-UNSATURATED AMIDE COMPOUND | Kyowa Kirin Co., Ltd. (JP) | 2020-09-23 | — | — | EP | disclosed |
| CN-110770211-A | α unsaturated amide compound | 协和麒麟株式会社 | 2020-02-07 | — | — | CN | disclosed |
| US-20190290645-A1 | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-09-26 | — | — | US | disclosed |
| US-5849755-A | 3-amidochromanylsulfonyl(thio)ureas, processes for their preparation, their use, and pharmaceutical preparations comprising them | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-12-15 | — | — | US | disclosed |
| EP-0842927-A1 | 3-Amido-chromanylsulfonyl(thio)ureas, process for their preparation, their use and medicaments containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-05-20 | — | — | EP | disclosed |
| EP-0161218-B1 | BENZO-(PYRANO AND THIOPYRANO)PYRIDINES | CIBA-GEIGY AG (CH) | 1991-06-26 | — | — | EP | disclosed |
| EP-0161218-A2 | Benzo-(pyrano and thiopyrano)pyridines | CIBA-GEIGY AG (CH) | 1985-11-13 | — | — | EP | disclosed |
| US-4548943-A | INHIBITS PROSTAGLADIN SYNTHETASE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-10-22 | — | — | US | disclosed |
| US-4548946-A | Antiinflammatory and/or analgesic 1,8-Dihydro-(or 3,8-dihydro)-8-aryl-2-[(substituted)thio]-indeno[1,2-d]imidazoles and their corresponding sulfoxides and sulfones | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-10-22 | — | — | US | disclosed |
| US-4371541-A | Antiinflammatory and/or analgesic 3,4-dihydro-(or 1,4-dihydro)-4-aryl-2-((substituted)thio)-(1)-benzopyrano(3,4-d)imidazoles and their corresponding sulfoxides and sulfones | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1983-02-01 | — | — | US | disclosed |
| EP-0061712-A1 | Antiinflammatory and/or analgesic 1,8-dihydro (or 3,8-dihydro)-8-aryl-2-((substituted)thio)-indeno(1,2-)imidazoles and their corresponding sulfoxides and sulfones | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1982-10-06 | — | — | EP | disclosed |
| EP-0057932-A1 | Antiinflammatory and/or analgesic 3,4-dihydro(or 1,4-dihydro)-2-((substituted)thiol)-(1)-benzopyrano(3,4-d)imidazoles and their corresponding sulfoxides and sulfones | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1982-08-18 | — | — | EP | disclosed |
| US-4305954-A | Antiinflammatory 3,4-dihydro(or 1,4-dihydro)-2-[(substituted)thio]-[1]benzopyrano[3,4-d]imidazoles and their corresponding sulfoxides and sulfones | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155612-A1 | Alpha,Beta-UNSATURATED AMIDE COMPOUND | NR1H2, NR1H3, RXRA | CYP19A1 474/4885MAOB 3240/4885PKM 4731/4885 |
| US-11447471-B2 | α,β-unsaturated amide compound | NR1H2, RXRA, RXRB | CYP19A1 404/4885MAOB 3184/4885PKM 4699/4885 |
| US-10787428-B2 | α,β-unsaturated amide compound | NR1H2, NCOA1, NR0B1 | CYP19A1 269/4885MAOB 3552/4885PKM 4397/4885 |
| US-20210380551-A1 | ALPHA,BETA-UNSATURATED AMIDE COMPOUND | NR1H2, NR1H3, NCOA1 | CYP19A1 302/4885MAOB 3686/4885PKM 4437/4885 |
| US-11332455-B2 | α,β-unsaturated amide compound | NR1H2, NCOA1, NR0B1 | CYP19A1 269/4885MAOB 3552/4885PKM 4397/4885 |
| US-20190290645-A1 | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy | SLC7A1, BCAT1, AADAT | CYP19A1 1166/4885MAOB 2162/4885PKM 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.